Global Acute Lymphocytic/Lymphoblastic leukemia Market 2015-2019

2015-11-11
Price :
Published : Nov-2015
No. of Pages : 65

Global Acute Lymphocytic Leukemia Market 2015-2019

Covering: An in-depth study of the acute lymphocytic leukemia market and segmentation by route of administration (oral and parenteral), by type of molecules (biologics and small molecules), and by geography (the Americas, EMEA, and APAC). The report also presents a detailed analysis of the top companies operating in the market, including Amgen, Bristol-Myers Squibb, and Novartis.

Market landscape of acute lymphocytic leukemia

Acute lymphocytic leukemia or acute lymphoblastic leukemia, is a malignancy of the blood cells that affects the lymphoblasts or leukemic blasts, which witnesses an uncontrolled cell division. The main symptoms a patient exhibits are weakness, tiredness, dizziness, fever, shortness of breath, frequent infections, bruising, and bleeding.

Currently, the disease cannot be cured completely but the risk can be reduced by administering medication.

The market research analysts expect the global acute lymphocytic leukemia market to grow at a steady rate and post a CAGR of over 4% during the forecast period. One of the major factors contributing to the growth of the market is the provision for orphan drugs. For instance, in the US, orphan designation for a drug means incentives like tax credits for qualified clinical testing, exemption from prescription drug user fees unless indicated for additional non-orphan indications, and market exclusivity for seven years.

Segmentation of the acute lymphocytic leukemia market by route of administration

  • Oral
  • Parenteral

Many medications are administered through the oral route to guarantee a systemic effect. The oral route is a sub-division of enteral administration and is considered to be one of the safest and most preferred routes of drug administration.

Geographical segmentation of the acute lymphocytic leukemia market

  • Americas
  • APAC
  • EMEA

With a share of over 49%, the Americas dominated the acute lymphocytic leukemia market, with the US being the major revenue contributor. The Americas is closely followed by the EMEA and the APAC region and the market is expected to follow a similar trend during the forecast period.

Competitive landscape and key vendors

The acute lymphocytic leukemia market is marked by the presence of both global and local drug manufacturers with varied product portfolios containing generic and off- label drugs as well as branded therapies. Besides, the high level of unmet medical need is expected to give a platform to the vendors to develop products to cater to relevant areas and enhance their market shares.

Primary vendors in this market are –

  • Amgen
  • Bristol-Myers Squibb
  • Novartis

Other prominent vendors included in this report are Ariad, Arno Therapeutics, Baxter, Boehringer Ingelheim, ERYTECH Pharma, Fate Therapeutics, Jazz Pharmaceuticals, Orphan Europe, Otsuka, Ono Pharmaceuticals, Onconova Therapeutics, Pfizer, Regeneron Pharmaceuticals, Sanofi, and Sigma-Tau Pharmaceuticals.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2019?
  • What are the key factors driving the global acute lymphocytic leukemia market?
  • What are the key market trends impacting the growth of the global acute lymphocytic leukemia market?
  • What are the challenges to market growth?
  • Who are the key vendors in the global acute lymphocytic leukemia market?
  • What are the market opportunities and threats faced by the vendors in the global acute lymphocytic leukemia market?
  • What are the trending factors influencing the market shares of the Americas, EMEA, and APAC?
  • What are the key outcomes of the five forces analysis of the global acute lymphocytic leukemia market?
Filed in: Pharmaceutical, Therapeutics
Publisher : Technavio
More Reports
Title Price Buy Now

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – New Zealand

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - New Zealand Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - New Zealand". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in New Zealand. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of New Zealand. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, a......
$1995

Partnerships, Licensing, Investments and M&A Deals and Trends for 2017 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for 2017 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for 2017 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2017. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on th......
$3500

Osteoporosis: Epidemiology Forecast to 2027

Osteoporosis: Epidemiology Forecast to 2027 Summary Osteoporosis is a disease in which the density and quality of bone are reduced over time. In a normal process known as remodeling, some of a person's bone cells dissolve (resorption) and new bone cells grow back (formation). The bones become so weak and brittle that a fall or even mild stresses such as bending over or coughing can cause a fracture. To forecast the total prevalent cases and diagnosed prevalent cases of osteoporosis and osteopenia in the 7MM, GlobalData epidemiologists selected nationally representative, population-based studies that provided these epidemiological data in the 7MM. GlobalData epidemiologists obtained data for the total prevalent cases of osteoporosis secondary to glucocorticoid use from primary market res......
$3995

PharmSource – CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance – 2018 Edition

PharmSource - CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance - 2018 Edition Summary This report is the 8th edition of our long running analysis of the CMO Industry, using NDA approvals as the primary indicator of performance. CMO Scorecard is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs. Reasons to buy This 43-page report gives important, expert insight you won't find in any other source. 28 tables and figures throughout the report illustrate major points and trends. This report is required reading for - - CMO executives who must have deep understanding of the injectables marketplace to make strategic planning and investment decisions. - Sourcing and procurement executives who must understand crucial componen......
$4995

Partnerships, Licensing, Investments and M&A Deals and Trends for February 2018 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for February 2018 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for February 2018 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in February 2018. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report......
$1000

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Belgium

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Belgium Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Belgium". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Belgium. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Belgium. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house anal......
$1995

Transdermal Drug Delivery – Medical Devices Pipeline Assessment, 2018

Transdermal Drug Delivery - Medical Devices Pipeline Assessment, 2018 Summary GlobalData's Medical Devices sector report, "Transdermal Drug Delivery - Medical Devices Pipeline Assessment, 2018" provides an overview of Transdermal Drug Delivery currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Transdermal Drug Delivery pipeline products. This report is prepared using data sourced from in-house databases, secondary......
$4000

Auto-Immune Diseases Diagnostic Tests – Medical Devices Pipeline Assessment, 2018

Auto-Immune Diseases Diagnostic Tests - Medical Devices Pipeline Assessment, 2018 Summary GlobalData's Medical Devices sector report, "Auto-Immune Diseases Diagnostic Tests - Medical Devices Pipeline Assessment, 2018" provides an overview of Auto-Immune Diseases Diagnostic Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Auto-Immune Diseases Diagnostic Tests pipeline products. This report is prepared using......
$4000

Head and Neck Cancers: Epidemiology Forecast to 2026

Head and Neck Cancers: Epidemiology Forecast to 2026 Summary Head and neck cancers usually begin in the squamous cells that line the moist mucosal surfaces of the tissues and organs of the head and neck-more than 83% of all oral cavity and pharynx cancers are squamous cell carcinomas. They are the ninth most common malignancy in the world, with high mortality rates in the developing countries. 10-year epidemiological forecasts of the diagnosed incident cases of HNCs are provided. HNCs are grouped into the following, in this report - 1. Cancers of the lip, oral cavity, pharynx, and larynx cancer (ICD-10 = C00-C06, C09-C10, C12-C14, and C32) 2. Oropharynx cancer (ICD-10 = C10) 3. Nasopharynx cancer (ICD-10 = C11) 4. Other head and neck cancer sites - salivary gland and nose, sinuses, and......
$3995

Non-Rhabdomyosarcoma Global Clinical Trials Review, H1, 2018

Non-Rhabdomyosarcoma Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Non-Rhabdomyosarcoma Global Clinical Trials Review, H1, 2018" provides an overview of Non-Rhabdomyosarcoma clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Rhabdomyosarcoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinic......
$2500